bt474  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    ATCC bt474
    β-escin induces apoptosis in trastuzumab-sensitive and –resistant cells. A Chemical structure of β-escin. B The changes in morphology of <t>BT474</t> and SKBR3 cells after treatment of β-escin (10-20 μM, 48 h) as observed by phase-contrast microscopy. C Representative phase-contrast images of JIMT-1 and MDA-MB-453 cells after treatment with β-escin (10-30 μM, 48 h). D , E Trastuzumab-sensitive SKBR3 and BT474 cells ( D ) and trastuzumab-resistant MDA-MB-453 and JIMT-1 cells ( E ) were treated with various concentrations of β-escin (1-100 μM) for 48 h, and cell viability was evaluated by MTS assay (**** p
    Bt474, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt474/product/ATCC
    Average 98 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    bt474 - by Bioz Stars, 2022-11
    98/100 stars

    Images

    1) Product Images from "β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features"

    Article Title: β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features

    Journal: Cancer Cell International

    doi: 10.1186/s12935-022-02713-9

    β-escin induces apoptosis in trastuzumab-sensitive and –resistant cells. A Chemical structure of β-escin. B The changes in morphology of BT474 and SKBR3 cells after treatment of β-escin (10-20 μM, 48 h) as observed by phase-contrast microscopy. C Representative phase-contrast images of JIMT-1 and MDA-MB-453 cells after treatment with β-escin (10-30 μM, 48 h). D , E Trastuzumab-sensitive SKBR3 and BT474 cells ( D ) and trastuzumab-resistant MDA-MB-453 and JIMT-1 cells ( E ) were treated with various concentrations of β-escin (1-100 μM) for 48 h, and cell viability was evaluated by MTS assay (**** p
    Figure Legend Snippet: β-escin induces apoptosis in trastuzumab-sensitive and –resistant cells. A Chemical structure of β-escin. B The changes in morphology of BT474 and SKBR3 cells after treatment of β-escin (10-20 μM, 48 h) as observed by phase-contrast microscopy. C Representative phase-contrast images of JIMT-1 and MDA-MB-453 cells after treatment with β-escin (10-30 μM, 48 h). D , E Trastuzumab-sensitive SKBR3 and BT474 cells ( D ) and trastuzumab-resistant MDA-MB-453 and JIMT-1 cells ( E ) were treated with various concentrations of β-escin (1-100 μM) for 48 h, and cell viability was evaluated by MTS assay (**** p

    Techniques Used: Microscopy, Multiple Displacement Amplification, MTS Assay

    β-escin-induced apoptosis is associated with activation of caspases and dysregulation of mitochondrial proteins. A , B The effects of β-escin (10-30 μM, 48 h) on apoptotic-related proteins. BT474 and JIMT-1 cells were treated with β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. The expression of cleaved-caspase-7, cleaved-caspase-3, and cleaved-PARP were upregulated in both BT474 ( A ) and JIMT-1 cells ( B ). Quantitative graphs of protein content are shown in the right panels (* p
    Figure Legend Snippet: β-escin-induced apoptosis is associated with activation of caspases and dysregulation of mitochondrial proteins. A , B The effects of β-escin (10-30 μM, 48 h) on apoptotic-related proteins. BT474 and JIMT-1 cells were treated with β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. The expression of cleaved-caspase-7, cleaved-caspase-3, and cleaved-PARP were upregulated in both BT474 ( A ) and JIMT-1 cells ( B ). Quantitative graphs of protein content are shown in the right panels (* p

    Techniques Used: Activation Assay, Expressing

    β-escin impairs CSC-like properties. A , B BT474 and JIMT-1 cells were treated with β-escin (10-30 μM) for 48 h and ALDH1 activity was assessed by flow cytometry. DEAB was used to define the baseline of Aldefluor-positive fluorescence. The quantitative graphs represent the percentage of Aldefluor-positive cells in BT474 (A, *** p
    Figure Legend Snippet: β-escin impairs CSC-like properties. A , B BT474 and JIMT-1 cells were treated with β-escin (10-30 μM) for 48 h and ALDH1 activity was assessed by flow cytometry. DEAB was used to define the baseline of Aldefluor-positive fluorescence. The quantitative graphs represent the percentage of Aldefluor-positive cells in BT474 (A, *** p

    Techniques Used: Activity Assay, Flow Cytometry, Fluorescence

    β-escin downregulates HER2, p95HER2, HER3 and Akt expression. A – D Western blots for HER2, p95HER2, phospho-HER2 (Y1221/1222), phospho-p95HER2, HER3, phospho-HER3 (Y1289), Akt, and phospho-Akt expression in BT474 ( A , C ) and JIMT-1 cells ( B , D ) following exposure to β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. GAPDH was used as an internal loading control. The ratio of the protein content is represented in the right panels (* p
    Figure Legend Snippet: β-escin downregulates HER2, p95HER2, HER3 and Akt expression. A – D Western blots for HER2, p95HER2, phospho-HER2 (Y1221/1222), phospho-p95HER2, HER3, phospho-HER3 (Y1289), Akt, and phospho-Akt expression in BT474 ( A , C ) and JIMT-1 cells ( B , D ) following exposure to β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. GAPDH was used as an internal loading control. The ratio of the protein content is represented in the right panels (* p

    Techniques Used: Expressing, Western Blot

    2) Product Images from "β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features"

    Article Title: β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features

    Journal: Cancer Cell International

    doi: 10.1186/s12935-022-02713-9

    β-escin induces apoptosis in trastuzumab-sensitive and –resistant cells. A Chemical structure of β-escin. B The changes in morphology of BT474 and SKBR3 cells after treatment of β-escin (10-20 μM, 48 h) as observed by phase-contrast microscopy. C Representative phase-contrast images of JIMT-1 and MDA-MB-453 cells after treatment with β-escin (10-30 μM, 48 h). D , E Trastuzumab-sensitive SKBR3 and BT474 cells ( D ) and trastuzumab-resistant MDA-MB-453 and JIMT-1 cells ( E ) were treated with various concentrations of β-escin (1-100 μM) for 48 h, and cell viability was evaluated by MTS assay (**** p
    Figure Legend Snippet: β-escin induces apoptosis in trastuzumab-sensitive and –resistant cells. A Chemical structure of β-escin. B The changes in morphology of BT474 and SKBR3 cells after treatment of β-escin (10-20 μM, 48 h) as observed by phase-contrast microscopy. C Representative phase-contrast images of JIMT-1 and MDA-MB-453 cells after treatment with β-escin (10-30 μM, 48 h). D , E Trastuzumab-sensitive SKBR3 and BT474 cells ( D ) and trastuzumab-resistant MDA-MB-453 and JIMT-1 cells ( E ) were treated with various concentrations of β-escin (1-100 μM) for 48 h, and cell viability was evaluated by MTS assay (**** p

    Techniques Used: Microscopy, Multiple Displacement Amplification, MTS Assay

    β-escin-induced apoptosis is associated with activation of caspases and dysregulation of mitochondrial proteins. A , B The effects of β-escin (10-30 μM, 48 h) on apoptotic-related proteins. BT474 and JIMT-1 cells were treated with β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. The expression of cleaved-caspase-7, cleaved-caspase-3, and cleaved-PARP were upregulated in both BT474 ( A ) and JIMT-1 cells ( B ). Quantitative graphs of protein content are shown in the right panels (* p
    Figure Legend Snippet: β-escin-induced apoptosis is associated with activation of caspases and dysregulation of mitochondrial proteins. A , B The effects of β-escin (10-30 μM, 48 h) on apoptotic-related proteins. BT474 and JIMT-1 cells were treated with β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. The expression of cleaved-caspase-7, cleaved-caspase-3, and cleaved-PARP were upregulated in both BT474 ( A ) and JIMT-1 cells ( B ). Quantitative graphs of protein content are shown in the right panels (* p

    Techniques Used: Activation Assay, Expressing

    β-escin impairs CSC-like properties. A , B BT474 and JIMT-1 cells were treated with β-escin (10-30 μM) for 48 h and ALDH1 activity was assessed by flow cytometry. DEAB was used to define the baseline of Aldefluor-positive fluorescence. The quantitative graphs represent the percentage of Aldefluor-positive cells in BT474 (A, *** p
    Figure Legend Snippet: β-escin impairs CSC-like properties. A , B BT474 and JIMT-1 cells were treated with β-escin (10-30 μM) for 48 h and ALDH1 activity was assessed by flow cytometry. DEAB was used to define the baseline of Aldefluor-positive fluorescence. The quantitative graphs represent the percentage of Aldefluor-positive cells in BT474 (A, *** p

    Techniques Used: Activity Assay, Flow Cytometry, Fluorescence

    β-escin downregulates HER2, p95HER2, HER3 and Akt expression. A – D Western blots for HER2, p95HER2, phospho-HER2 (Y1221/1222), phospho-p95HER2, HER3, phospho-HER3 (Y1289), Akt, and phospho-Akt expression in BT474 ( A , C ) and JIMT-1 cells ( B , D ) following exposure to β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. GAPDH was used as an internal loading control. The ratio of the protein content is represented in the right panels (* p
    Figure Legend Snippet: β-escin downregulates HER2, p95HER2, HER3 and Akt expression. A – D Western blots for HER2, p95HER2, phospho-HER2 (Y1221/1222), phospho-p95HER2, HER3, phospho-HER3 (Y1289), Akt, and phospho-Akt expression in BT474 ( A , C ) and JIMT-1 cells ( B , D ) following exposure to β-escin (10-20 μM and 20-30 μM, respectively) for 48 h. GAPDH was used as an internal loading control. The ratio of the protein content is represented in the right panels (* p

    Techniques Used: Expressing, Western Blot

    3) Product Images from "Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness"

    Article Title: Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness

    Journal: Neoplasia (New York, N.Y.)

    doi: 10.1016/j.neo.2022.100836

    Forced expression of TRAF3 in BT474-RANK-c cell is able to reverse the aggressive cell phenotype. (A) Colony formation assay and quantification of BT474-RANK-c and parental cells (control) transiently transfected with a TRAF3 plasmid or an inactive TRAF3 mutant plasmid (TRAF3mut). (B) Transwell migration assay and quantification of BT474-RANK-c and control cells after transient transfection with the indicated plasmid constructs for TRAF3 (TRAF3 and TRAF3mut). (C) Matrigel invasion assay and quantification of BT474-RANK-c and control cells after transient transfection with the indicated plasmid constructs (as for migration).
    Figure Legend Snippet: Forced expression of TRAF3 in BT474-RANK-c cell is able to reverse the aggressive cell phenotype. (A) Colony formation assay and quantification of BT474-RANK-c and parental cells (control) transiently transfected with a TRAF3 plasmid or an inactive TRAF3 mutant plasmid (TRAF3mut). (B) Transwell migration assay and quantification of BT474-RANK-c and control cells after transient transfection with the indicated plasmid constructs for TRAF3 (TRAF3 and TRAF3mut). (C) Matrigel invasion assay and quantification of BT474-RANK-c and control cells after transient transfection with the indicated plasmid constructs (as for migration).

    Techniques Used: Expressing, Colony Assay, Transfection, Plasmid Preparation, Mutagenesis, Transwell Migration Assay, Construct, Invasion Assay, Migration

    RANK-c differentially affects multiple signalling pathways in SKBR3 and BT474 cells. (A) Western blot analyses for the indicated proteins in SKBR3 and BT474 cells (RANK-c and control). (B) Representative images and quantification of immunofluorescence staining of SKBR3-RANK-c, BT474-RANK-c and control cells for RANK-c and p65 protein localization. Split channels at 40x magnification. (C) Western blot analysis of RANK-c expressing SKBR3 and BT474 cell lysates immunoprecipitated with an antibody against RANK (AF683) and blotted for endogenous TRAF2 protein.
    Figure Legend Snippet: RANK-c differentially affects multiple signalling pathways in SKBR3 and BT474 cells. (A) Western blot analyses for the indicated proteins in SKBR3 and BT474 cells (RANK-c and control). (B) Representative images and quantification of immunofluorescence staining of SKBR3-RANK-c, BT474-RANK-c and control cells for RANK-c and p65 protein localization. Split channels at 40x magnification. (C) Western blot analysis of RANK-c expressing SKBR3 and BT474 cell lysates immunoprecipitated with an antibody against RANK (AF683) and blotted for endogenous TRAF2 protein.

    Techniques Used: Western Blot, Immunofluorescence, Staining, Expressing, Immunoprecipitation

    RANK-c expression in SKBR3 and BT474 cells differentially affects aggressive properties. (A) Phase-contrast images of 2D cell cultures in standard media depicting morphological changes upon RANK-c expression. SKBR3-RANK-c cells lose their fibroblast-like appearance, while in the contrary BT474 cells lose coherence and attain a spindle-cell morphology. (B) Western blot of SKBR3 and BT474 cells extracts showing the downregulation and upregulation of Fibronectin and Snail upon RANK-c expression, respectively. (C) Representative images and quantification of colony formation by SKBR3-RANK-c and BT474-RANK-c cells in relevance to the respective control cells ( n = 3 wells per group). (D) Transwell migration quantification for SKBR3-RANK-c, BT474-RANK-c and control cells ( n = = 3). (E) Matrigel invasion assay and quantification for SKBR3-RANK-c, BT474-RANK-c and control cells ( n = = 3).
    Figure Legend Snippet: RANK-c expression in SKBR3 and BT474 cells differentially affects aggressive properties. (A) Phase-contrast images of 2D cell cultures in standard media depicting morphological changes upon RANK-c expression. SKBR3-RANK-c cells lose their fibroblast-like appearance, while in the contrary BT474 cells lose coherence and attain a spindle-cell morphology. (B) Western blot of SKBR3 and BT474 cells extracts showing the downregulation and upregulation of Fibronectin and Snail upon RANK-c expression, respectively. (C) Representative images and quantification of colony formation by SKBR3-RANK-c and BT474-RANK-c cells in relevance to the respective control cells ( n = 3 wells per group). (D) Transwell migration quantification for SKBR3-RANK-c, BT474-RANK-c and control cells ( n = = 3). (E) Matrigel invasion assay and quantification for SKBR3-RANK-c, BT474-RANK-c and control cells ( n = = 3).

    Techniques Used: Expressing, Western Blot, Migration, Invasion Assay

    TRAF3 is absent from the RANK-c/TRAF2 complex in BT474 cells. (A) Volcano plots of RANK-c-enriched samples compared to their controls in SKBR3 and BT474 cells. The lines represent significance cut-offs of a 1% and 5% FDR with an S0 value of 0.1. All proteins identified in this experiment are listed in Supplementary Table 1. (B) Western blot analysis of SKBR3-RANK-c and BT474-RANK-c cell lysates immunoprecipitated with an antibody against RANK (AF683) and blotted for endogenous TRAF2 and TRAF3 proteins. (C) Western blot analysis of 293T cells transiently transfected with the indicated plasmid constructs and subsequently lysed and immunoprecipitated with an antibody against TRAF2 (sc-136999) and blotted for RANK-c and TRAF3 proteins.
    Figure Legend Snippet: TRAF3 is absent from the RANK-c/TRAF2 complex in BT474 cells. (A) Volcano plots of RANK-c-enriched samples compared to their controls in SKBR3 and BT474 cells. The lines represent significance cut-offs of a 1% and 5% FDR with an S0 value of 0.1. All proteins identified in this experiment are listed in Supplementary Table 1. (B) Western blot analysis of SKBR3-RANK-c and BT474-RANK-c cell lysates immunoprecipitated with an antibody against RANK (AF683) and blotted for endogenous TRAF2 and TRAF3 proteins. (C) Western blot analysis of 293T cells transiently transfected with the indicated plasmid constructs and subsequently lysed and immunoprecipitated with an antibody against TRAF2 (sc-136999) and blotted for RANK-c and TRAF3 proteins.

    Techniques Used: Western Blot, Immunoprecipitation, Transfection, Plasmid Preparation, Construct

    4) Product Images from "A comprehensive role evaluation and mechanism exploration of POGLUT2 in pan-cancer"

    Article Title: A comprehensive role evaluation and mechanism exploration of POGLUT2 in pan-cancer

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2022.962540

    Gene and protein expression evaluation of POGLUT2 in breast cancer cells and tissues. (A) Gene expression of POGLUT2 was determined in four breast cancer cell lines, including MDA-MB-468, MDA-MB-231, MCF-7, and BT474, and highest expression was found in MCF-7 cells. (B) Protein expression of POGLUT2 was determined in four breast cancer cell lines, including MDA-MB-468, MDA-MB-231, MCF-7, and BT474, and highest expression was found in MDA-MB-231 cells. (C) Immunohistochemistry analysis of POGLUT2 in breast cancer tissues compared to control tissues. (D) Significant POGLUT2 expression downregulation was found in MCF-7 cells after siRNA transfection. (E) Significantly POGLUT2 expression downregulation was found in MDA-MB-231 cells after siRNA transfection. (F) Significantly POGLUT2 protein level downregulation was found in MCF-7 cells after siRNA transfection. (G) Significantly POGLUT2 protein level downregulation was found in MDA-MB-231 cells after siRNA transfection. * p
    Figure Legend Snippet: Gene and protein expression evaluation of POGLUT2 in breast cancer cells and tissues. (A) Gene expression of POGLUT2 was determined in four breast cancer cell lines, including MDA-MB-468, MDA-MB-231, MCF-7, and BT474, and highest expression was found in MCF-7 cells. (B) Protein expression of POGLUT2 was determined in four breast cancer cell lines, including MDA-MB-468, MDA-MB-231, MCF-7, and BT474, and highest expression was found in MDA-MB-231 cells. (C) Immunohistochemistry analysis of POGLUT2 in breast cancer tissues compared to control tissues. (D) Significant POGLUT2 expression downregulation was found in MCF-7 cells after siRNA transfection. (E) Significantly POGLUT2 expression downregulation was found in MDA-MB-231 cells after siRNA transfection. (F) Significantly POGLUT2 protein level downregulation was found in MCF-7 cells after siRNA transfection. (G) Significantly POGLUT2 protein level downregulation was found in MDA-MB-231 cells after siRNA transfection. * p

    Techniques Used: Expressing, Multiple Displacement Amplification, Immunohistochemistry, Transfection

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • bt 474  (ATCC)
    98
    ATCC bt 474
    The g3mclass autoclassification on three genes. ( A ) The g3mclass -selected models. The 5-class model parameters for ESR1 mRNA: class − 1 (0.49 ± 0.57; weight 0.25); class 0 (3.34 ± 3.18; weight 0.27), class 1 (17.4 ± 9.22; weight 0.25), class 2 (63.4 ± 29.2; weight 0.19), class 3 (99.5 ± 105; weight 0.05). The 4-class model parameters for PGR mRNA: class − 1 (0.30 ± 0.43; weight 0.48); class 0 (3.09 ± 2.77; weight 0.26), class 1 (7.88 ± 3.49; weight 0.13), class 2 (63.4 ± 29.2; weight 0.12). The 4-class model parameters for ERBB2 mRNA as above in Fig. 2 . ( B )–( E ) The g3mclass -created classification heatmaps. The s.cutoff classification heatmaps on ESR1, PGR, and ERBB2 for mammoplasties ( B ), IBC ( C ), DCIS ( D ), and IBC cell lines ( E ). The IHC score for ER-positive (1), and ER-negative (0) cancers are on the top of heatmaps ( C , D ). In E, human breast cancer cell lines: MDA-MB-231 (triple-negative), SK-BR-3 (HER2 overexpressing), <t>BT-474</t> (luminal B), T47D (luminal A), MCF7 (luminal A). Bar, heatmap’s color scale for classes.
    Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/ATCC
    Average 98 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2022-11
    98/100 stars
      Buy from Supplier

    bt 20  (ATCC)
    95
    ATCC bt 20
    The g3mclass autoclassification on three genes. ( A ) The g3mclass -selected models. The 5-class model parameters for ESR1 mRNA: class − 1 (0.49 ± 0.57; weight 0.25); class 0 (3.34 ± 3.18; weight 0.27), class 1 (17.4 ± 9.22; weight 0.25), class 2 (63.4 ± 29.2; weight 0.19), class 3 (99.5 ± 105; weight 0.05). The 4-class model parameters for PGR mRNA: class − 1 (0.30 ± 0.43; weight 0.48); class 0 (3.09 ± 2.77; weight 0.26), class 1 (7.88 ± 3.49; weight 0.13), class 2 (63.4 ± 29.2; weight 0.12). The 4-class model parameters for ERBB2 mRNA as above in Fig. 2 . ( B )–( E ) The g3mclass -created classification heatmaps. The s.cutoff classification heatmaps on ESR1, PGR, and ERBB2 for mammoplasties ( B ), IBC ( C ), DCIS ( D ), and IBC cell lines ( E ). The IHC score for ER-positive (1), and ER-negative (0) cancers are on the top of heatmaps ( C , D ). In E, human breast cancer cell lines: MDA-MB-231 (triple-negative), SK-BR-3 (HER2 overexpressing), <t>BT-474</t> (luminal B), T47D (luminal A), MCF7 (luminal A). Bar, heatmap’s color scale for classes.
    Bt 20, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 20/product/ATCC
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 20 - by Bioz Stars, 2022-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    The g3mclass autoclassification on three genes. ( A ) The g3mclass -selected models. The 5-class model parameters for ESR1 mRNA: class − 1 (0.49 ± 0.57; weight 0.25); class 0 (3.34 ± 3.18; weight 0.27), class 1 (17.4 ± 9.22; weight 0.25), class 2 (63.4 ± 29.2; weight 0.19), class 3 (99.5 ± 105; weight 0.05). The 4-class model parameters for PGR mRNA: class − 1 (0.30 ± 0.43; weight 0.48); class 0 (3.09 ± 2.77; weight 0.26), class 1 (7.88 ± 3.49; weight 0.13), class 2 (63.4 ± 29.2; weight 0.12). The 4-class model parameters for ERBB2 mRNA as above in Fig. 2 . ( B )–( E ) The g3mclass -created classification heatmaps. The s.cutoff classification heatmaps on ESR1, PGR, and ERBB2 for mammoplasties ( B ), IBC ( C ), DCIS ( D ), and IBC cell lines ( E ). The IHC score for ER-positive (1), and ER-negative (0) cancers are on the top of heatmaps ( C , D ). In E, human breast cancer cell lines: MDA-MB-231 (triple-negative), SK-BR-3 (HER2 overexpressing), BT-474 (luminal B), T47D (luminal A), MCF7 (luminal A). Bar, heatmap’s color scale for classes.

    Journal: Scientific Reports

    Article Title: The g3mclass is a practical software for multiclass classification on biomarkers

    doi: 10.1038/s41598-022-23438-9

    Figure Lengend Snippet: The g3mclass autoclassification on three genes. ( A ) The g3mclass -selected models. The 5-class model parameters for ESR1 mRNA: class − 1 (0.49 ± 0.57; weight 0.25); class 0 (3.34 ± 3.18; weight 0.27), class 1 (17.4 ± 9.22; weight 0.25), class 2 (63.4 ± 29.2; weight 0.19), class 3 (99.5 ± 105; weight 0.05). The 4-class model parameters for PGR mRNA: class − 1 (0.30 ± 0.43; weight 0.48); class 0 (3.09 ± 2.77; weight 0.26), class 1 (7.88 ± 3.49; weight 0.13), class 2 (63.4 ± 29.2; weight 0.12). The 4-class model parameters for ERBB2 mRNA as above in Fig. 2 . ( B )–( E ) The g3mclass -created classification heatmaps. The s.cutoff classification heatmaps on ESR1, PGR, and ERBB2 for mammoplasties ( B ), IBC ( C ), DCIS ( D ), and IBC cell lines ( E ). The IHC score for ER-positive (1), and ER-negative (0) cancers are on the top of heatmaps ( C , D ). In E, human breast cancer cell lines: MDA-MB-231 (triple-negative), SK-BR-3 (HER2 overexpressing), BT-474 (luminal B), T47D (luminal A), MCF7 (luminal A). Bar, heatmap’s color scale for classes.

    Article Snippet: The cell lines MCF-7T-47D, MDA-MB-231, SK-BR-3, and BT-474 were purchased from the American Type Culture Collection and cultured accordingly.

    Techniques: Immunohistochemistry, Multiple Displacement Amplification

    LINC00847-FOXA1 and CTD-2566J3.1 GINS2 are essential genes for proliferation and survival. ( A ) DEMETER score values for each mRNA reported in the co-expressed mRNAs/lncRNAs pairs of 3D cultures and TCGA data. ( B , C ) The DEMETER score is shown against the gene expression of FOXA1 and GINS2 ; the stars represent BT-474 cell line and the color dots represent the breast cancer subtype of each cell line.

    Journal: Cells

    Article Title: Breast Cancer Cells Reprogram the Oncogenic lncRNAs/mRNAs Coexpression Networks in Three-Dimensional Microenvironment

    doi: 10.3390/cells11213458

    Figure Lengend Snippet: LINC00847-FOXA1 and CTD-2566J3.1 GINS2 are essential genes for proliferation and survival. ( A ) DEMETER score values for each mRNA reported in the co-expressed mRNAs/lncRNAs pairs of 3D cultures and TCGA data. ( B , C ) The DEMETER score is shown against the gene expression of FOXA1 and GINS2 ; the stars represent BT-474 cell line and the color dots represent the breast cancer subtype of each cell line.

    Article Snippet: BT-474 cell lines were obtained from ATCC (Manassas, Virginia) and cultured in Hybri-Care medium and 10% fetal bovine serum (FBS).

    Techniques: Expressing

    Co-expression lncRNAs/mRNAs networks common in BT-474 cell grown in 3D cultures and breast tumors (TCGA). The diagram shows how the cellular processes associated to cancer hallmarks, could be regulated by ncRNAs/mRNAs pairs that are common in BT-474 cultures and breast biopsies. Blue dot: lncRNAs; green dot: mRNAs; pink dot; multiple colors; cancer hallmarks and therapy resistance.

    Journal: Cells

    Article Title: Breast Cancer Cells Reprogram the Oncogenic lncRNAs/mRNAs Coexpression Networks in Three-Dimensional Microenvironment

    doi: 10.3390/cells11213458

    Figure Lengend Snippet: Co-expression lncRNAs/mRNAs networks common in BT-474 cell grown in 3D cultures and breast tumors (TCGA). The diagram shows how the cellular processes associated to cancer hallmarks, could be regulated by ncRNAs/mRNAs pairs that are common in BT-474 cultures and breast biopsies. Blue dot: lncRNAs; green dot: mRNAs; pink dot; multiple colors; cancer hallmarks and therapy resistance.

    Article Snippet: BT-474 cell lines were obtained from ATCC (Manassas, Virginia) and cultured in Hybri-Care medium and 10% fetal bovine serum (FBS).

    Techniques: Expressing

    Generation and morphology of 3D organotypic cultures. ( A ) Growth kinetics of BT-474 cancer cells grown in 2D monolayers and 3D cell cultures observed in optical microscopy (20× and 40×) during 0–6 days incubation over Geltrex. ( B ) Quantification of the diameter of round-like structures in 3D cell cultures. ( C ) Quantification of the number of structures in 3D cultures at optimized seeding densities of 25,000 cells/well plate. ( D ) Hematoxylin and eosin staining of BT-474 cancer cells grown in 2D and 3D culture conditions. ( E ) Color image of 2D monolayers and 3D cell cultures using Identify Primary Objects module. Filter Objects module discards objects that have irregular shape or cell debris (magenta lines). ( F ) Quantification of number of nuclei present in 3D round-like structures. Values represent the mean ± SD from 3 independent experiments, using an unpaired Student’s t -test with unequal variances; * p

    Journal: Cells

    Article Title: Breast Cancer Cells Reprogram the Oncogenic lncRNAs/mRNAs Coexpression Networks in Three-Dimensional Microenvironment

    doi: 10.3390/cells11213458

    Figure Lengend Snippet: Generation and morphology of 3D organotypic cultures. ( A ) Growth kinetics of BT-474 cancer cells grown in 2D monolayers and 3D cell cultures observed in optical microscopy (20× and 40×) during 0–6 days incubation over Geltrex. ( B ) Quantification of the diameter of round-like structures in 3D cell cultures. ( C ) Quantification of the number of structures in 3D cultures at optimized seeding densities of 25,000 cells/well plate. ( D ) Hematoxylin and eosin staining of BT-474 cancer cells grown in 2D and 3D culture conditions. ( E ) Color image of 2D monolayers and 3D cell cultures using Identify Primary Objects module. Filter Objects module discards objects that have irregular shape or cell debris (magenta lines). ( F ) Quantification of number of nuclei present in 3D round-like structures. Values represent the mean ± SD from 3 independent experiments, using an unpaired Student’s t -test with unequal variances; * p

    Article Snippet: BT-474 cell lines were obtained from ATCC (Manassas, Virginia) and cultured in Hybri-Care medium and 10% fetal bovine serum (FBS).

    Techniques: Microscopy, Incubation, Staining

    Two LINC00589 -centered ceRNA networks in breast cancer. LncRNA LINC00589 serves as a ceRNA platform by sponging miR-100 and miR-452 and thereby relieves their repression of DLG5 and PRDM16 , which inhibits MUC4 transcription, resulting in counteractions of trastuzumab resistance, CSC-like properties, and multiple chemoresistance in HER2-positive breast cancer.

    Journal: NPJ Breast Cancer

    Article Title: LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

    doi: 10.1038/s41523-022-00484-0

    Figure Lengend Snippet: Two LINC00589 -centered ceRNA networks in breast cancer. LncRNA LINC00589 serves as a ceRNA platform by sponging miR-100 and miR-452 and thereby relieves their repression of DLG5 and PRDM16 , which inhibits MUC4 transcription, resulting in counteractions of trastuzumab resistance, CSC-like properties, and multiple chemoresistance in HER2-positive breast cancer.

    Article Snippet: BT474 human breast cancer cells (HER2-overexpression) were obtained from the American Type Culture Collection (catalog number HTB-20, ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS.

    Techniques:

    LINC00589 represses trastuzumab resistance, cancer stem cell-like properties, and multiple chemoresistance via DLG5 and PRDM16 . A – E WT SKBR3 and BT474 cells infected with sh- LINC00589 or sh-NC lentivirus were transfected with pCDNA (pC) - DLG5 or pC- PRDM16 for 48 h; or TR SKBR3 cells infected with Lv- LINC00589 or the Lv-NC were transfected with sh- DLG5 or sh- PRDM16 for 48 h. The relative cell viabilities of WT SKBR3 cells ( A ), BT474 cells ( B ) and TR SKBR3 cells ( C ) were quantified by CCK-8 assay. Apoptosis of TR cells were examined by flow cytometry assay ( D ) and the apoptosis rate was calculated ( E ). F – M LINC00589 - or NC- overexpressing TR cells were infected with sh-NC, sh- DLG5 or sh- PRDM16 lentivirus. Cells were cultured in soft agar for 21 days, representative images of colony formation were observed ( F ), and the number of colonies were calculated ( G ). Scale bar 100 μm. Cells were seeded in an ultra-low-attachment culture system. Represent images of mammosphere formation were observed ( H ), and numbers ( I ) and volumes ( J ) of mammospheres were calculated. Scale bar 100 μm. Data are shown as the mean ± SD of five random high-power fields (HPF) and were analyzed by two-tailed t test. * P

    Journal: NPJ Breast Cancer

    Article Title: LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

    doi: 10.1038/s41523-022-00484-0

    Figure Lengend Snippet: LINC00589 represses trastuzumab resistance, cancer stem cell-like properties, and multiple chemoresistance via DLG5 and PRDM16 . A – E WT SKBR3 and BT474 cells infected with sh- LINC00589 or sh-NC lentivirus were transfected with pCDNA (pC) - DLG5 or pC- PRDM16 for 48 h; or TR SKBR3 cells infected with Lv- LINC00589 or the Lv-NC were transfected with sh- DLG5 or sh- PRDM16 for 48 h. The relative cell viabilities of WT SKBR3 cells ( A ), BT474 cells ( B ) and TR SKBR3 cells ( C ) were quantified by CCK-8 assay. Apoptosis of TR cells were examined by flow cytometry assay ( D ) and the apoptosis rate was calculated ( E ). F – M LINC00589 - or NC- overexpressing TR cells were infected with sh-NC, sh- DLG5 or sh- PRDM16 lentivirus. Cells were cultured in soft agar for 21 days, representative images of colony formation were observed ( F ), and the number of colonies were calculated ( G ). Scale bar 100 μm. Cells were seeded in an ultra-low-attachment culture system. Represent images of mammosphere formation were observed ( H ), and numbers ( I ) and volumes ( J ) of mammospheres were calculated. Scale bar 100 μm. Data are shown as the mean ± SD of five random high-power fields (HPF) and were analyzed by two-tailed t test. * P

    Article Snippet: BT474 human breast cancer cells (HER2-overexpression) were obtained from the American Type Culture Collection (catalog number HTB-20, ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS.

    Techniques: Infection, Transfection, CCK-8 Assay, Flow Cytometry, Cell Culture, Two Tailed Test

    LINC00589 expression is associated with response to trastuzumab in HER2-positive breast cancer. A mRNA expression of LINC00589 in trastuzumab-responding ( N = 38) and non-responding ( N = 33) breast cancer patients was detected by qRT-PCR. Data were analyzed by a two-tailed t test. B ROC curve for LINC00589 expression to differentiate responding patients from non-responding patients. C The rate of trastuzumab-response patients was significantly higher in the high LINC00589 expression groups than in the low expression group. D In situ hybridization (ISH) staining of high and low expression of LINC00589 in formalin-fixed and paraffin-embedded tissues from HER2-positive breast cancer patients with trastuzumab treatment. Scale bar 50 μm. E Kaplan–Meier’s correlation analyses between LINC00589 expression and overall survival of patients (low, N = 43; high, N = 49). F The expression of LINC00589 in TR clone cells and WT cells was evaluated by qRT-PCR. Assays were conducted in triplicate. Data are shown as the means ± SD; data were analyzed by ANOVA and two-tailed t test. ** P

    Journal: NPJ Breast Cancer

    Article Title: LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

    doi: 10.1038/s41523-022-00484-0

    Figure Lengend Snippet: LINC00589 expression is associated with response to trastuzumab in HER2-positive breast cancer. A mRNA expression of LINC00589 in trastuzumab-responding ( N = 38) and non-responding ( N = 33) breast cancer patients was detected by qRT-PCR. Data were analyzed by a two-tailed t test. B ROC curve for LINC00589 expression to differentiate responding patients from non-responding patients. C The rate of trastuzumab-response patients was significantly higher in the high LINC00589 expression groups than in the low expression group. D In situ hybridization (ISH) staining of high and low expression of LINC00589 in formalin-fixed and paraffin-embedded tissues from HER2-positive breast cancer patients with trastuzumab treatment. Scale bar 50 μm. E Kaplan–Meier’s correlation analyses between LINC00589 expression and overall survival of patients (low, N = 43; high, N = 49). F The expression of LINC00589 in TR clone cells and WT cells was evaluated by qRT-PCR. Assays were conducted in triplicate. Data are shown as the means ± SD; data were analyzed by ANOVA and two-tailed t test. ** P

    Article Snippet: BT474 human breast cancer cells (HER2-overexpression) were obtained from the American Type Culture Collection (catalog number HTB-20, ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS.

    Techniques: Expressing, Quantitative RT-PCR, Two Tailed Test, In Situ Hybridization, Staining

    LINC00589 promotes the sensitivity of breast cancer cells to trastuzumab and inhibits anchorage-independent growth. A – C TR SKBR3 cells were infected with NC or LINC00589 -overexpression lentivirus and treated with 25 μg/ml trastuzumab. WT SKBR3 and BT474 cells were infected with sh-NC or sh- LINC00589 lentivirus and treated with 5 μg/ml trastuzumab treatment. The relative cell viabilities were determined by CCK-8 assays at the indicated times. D , E TR and WT SKBR3 cells were infected with overexpression or shRNA lentiviruses and then were treated with 25 μg/ml trastuzumab or 5 μg/ml trastuzumab for 48 h, followed by FITC-conjugated annexin V and PE-labeled PI staining. The apoptosis rate was analyzed by flow cytometry. F , G TR or WT SKBR3 cells were cultured in soft agar for 21 days after trastuzumab treatment and then subjected to crystal violet staining. The clones were observed, and the number of clones for each sample was calculated. Scale bar 100 μm. Data are represented as the mean ± SD of three replicates or are representative of three independent experiments. Two-way ANOVA were used to analyze the data in ( A – C ), and two-tailed t test was used to analyze the data in ( E , G ). * P

    Journal: NPJ Breast Cancer

    Article Title: LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

    doi: 10.1038/s41523-022-00484-0

    Figure Lengend Snippet: LINC00589 promotes the sensitivity of breast cancer cells to trastuzumab and inhibits anchorage-independent growth. A – C TR SKBR3 cells were infected with NC or LINC00589 -overexpression lentivirus and treated with 25 μg/ml trastuzumab. WT SKBR3 and BT474 cells were infected with sh-NC or sh- LINC00589 lentivirus and treated with 5 μg/ml trastuzumab treatment. The relative cell viabilities were determined by CCK-8 assays at the indicated times. D , E TR and WT SKBR3 cells were infected with overexpression or shRNA lentiviruses and then were treated with 25 μg/ml trastuzumab or 5 μg/ml trastuzumab for 48 h, followed by FITC-conjugated annexin V and PE-labeled PI staining. The apoptosis rate was analyzed by flow cytometry. F , G TR or WT SKBR3 cells were cultured in soft agar for 21 days after trastuzumab treatment and then subjected to crystal violet staining. The clones were observed, and the number of clones for each sample was calculated. Scale bar 100 μm. Data are represented as the mean ± SD of three replicates or are representative of three independent experiments. Two-way ANOVA were used to analyze the data in ( A – C ), and two-tailed t test was used to analyze the data in ( E , G ). * P

    Article Snippet: BT474 human breast cancer cells (HER2-overexpression) were obtained from the American Type Culture Collection (catalog number HTB-20, ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS.

    Techniques: Infection, Over Expression, CCK-8 Assay, shRNA, Labeling, Staining, Flow Cytometry, Cell Culture, Clone Assay, Two Tailed Test

    LINC00589 sponges miR-100 and miR-452 . a LINC00589 localization was predicted using the lncRNA subcellular localization predictor lncLocator. b , c LINC00589 localization was confirmed by subcellular fractionation assays in BT474 and SKBR3 cells. Nuclear control: U6; cytosolic control: GAPDH. d RNA immunoprecipitation experiments were performed in BT474 and SKBR3 cells, and the coprecipitated RNA was used to quantify LINC00589 expression by qRT-PCR. e Potential miRNAs binding to LINC00589 via miRNA- LINC00589 interaction were predicted by lncBase. Then the predicted miRNAs and the upregulated miRNAs in TR cells from GEO dataset (GSE47011) were overlapped. Nine candidate miRNAs were obtained for further investigation. f Luc- LINC00589 vector was co-transfected with the NC mimic (MIM) or the nine miRNAs MIM into TR cells for 48 h, followed by luciferase reporter assay. g Predicted miR-100 and miR-452 binding sites on LINC00589 and the mutations for luciferase reporter assay are shown. h , i Luciferase reporter plasmids containing wild type (WT) or mutant (Mut) LINC00589 were co-transfected with NC MIM, miR-100 MIM, or miR-452 MIM into TR cells for 48 h. Subsequently, the luciferase activity was evaluated. j MS2, MS2- LINC00589 or MS2- LINC00589 harboring mutations (Mut) in the miR-100 or miR-452 binding sites were transfected into WT cells for 48 h. Then, total RNA was incubated with MBP-MCP-conjugated amylose resin, and the immunoprecipitated RNA was subjected to qRT-PCR. k , l Expression of miR-100 and miR-452 in TR cells infected with Lv-NC or Lv- LINC00589 in WT cells infected with sh-NC or sh- LINC00589 was measured by qRT-PCR assay. U6 was used as an internal control. Data are shown as mean ± SD; two-tailed t test was used to analyze the data in ( d , f , h , I , j , k , and l ). * P

    Journal: NPJ Breast Cancer

    Article Title: LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

    doi: 10.1038/s41523-022-00484-0

    Figure Lengend Snippet: LINC00589 sponges miR-100 and miR-452 . a LINC00589 localization was predicted using the lncRNA subcellular localization predictor lncLocator. b , c LINC00589 localization was confirmed by subcellular fractionation assays in BT474 and SKBR3 cells. Nuclear control: U6; cytosolic control: GAPDH. d RNA immunoprecipitation experiments were performed in BT474 and SKBR3 cells, and the coprecipitated RNA was used to quantify LINC00589 expression by qRT-PCR. e Potential miRNAs binding to LINC00589 via miRNA- LINC00589 interaction were predicted by lncBase. Then the predicted miRNAs and the upregulated miRNAs in TR cells from GEO dataset (GSE47011) were overlapped. Nine candidate miRNAs were obtained for further investigation. f Luc- LINC00589 vector was co-transfected with the NC mimic (MIM) or the nine miRNAs MIM into TR cells for 48 h, followed by luciferase reporter assay. g Predicted miR-100 and miR-452 binding sites on LINC00589 and the mutations for luciferase reporter assay are shown. h , i Luciferase reporter plasmids containing wild type (WT) or mutant (Mut) LINC00589 were co-transfected with NC MIM, miR-100 MIM, or miR-452 MIM into TR cells for 48 h. Subsequently, the luciferase activity was evaluated. j MS2, MS2- LINC00589 or MS2- LINC00589 harboring mutations (Mut) in the miR-100 or miR-452 binding sites were transfected into WT cells for 48 h. Then, total RNA was incubated with MBP-MCP-conjugated amylose resin, and the immunoprecipitated RNA was subjected to qRT-PCR. k , l Expression of miR-100 and miR-452 in TR cells infected with Lv-NC or Lv- LINC00589 in WT cells infected with sh-NC or sh- LINC00589 was measured by qRT-PCR assay. U6 was used as an internal control. Data are shown as mean ± SD; two-tailed t test was used to analyze the data in ( d , f , h , I , j , k , and l ). * P

    Article Snippet: BT474 human breast cancer cells (HER2-overexpression) were obtained from the American Type Culture Collection (catalog number HTB-20, ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS.

    Techniques: Fractionation, Immunoprecipitation, Expressing, Quantitative RT-PCR, Binding Assay, Plasmid Preparation, Transfection, Luciferase, Reporter Assay, Mutagenesis, Activity Assay, Incubation, Infection, Two Tailed Test

    LINC00589 expression reverses cancer stem cell-like properties and multiple chemoresistance of HER2-positive breast cancer. A Representative image of mammosphere formation in NC- and LINC00589 - overexpressing TR breast cancer cells. Scale bar 100 μm. B , C Quantification of the mammosphere number ( B ) and volume ( C ). Data are shown as the mean ± SD of five random high-power fields (HPF), and were analyzed by two-tailed t test. * P

    Journal: NPJ Breast Cancer

    Article Title: LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer

    doi: 10.1038/s41523-022-00484-0

    Figure Lengend Snippet: LINC00589 expression reverses cancer stem cell-like properties and multiple chemoresistance of HER2-positive breast cancer. A Representative image of mammosphere formation in NC- and LINC00589 - overexpressing TR breast cancer cells. Scale bar 100 μm. B , C Quantification of the mammosphere number ( B ) and volume ( C ). Data are shown as the mean ± SD of five random high-power fields (HPF), and were analyzed by two-tailed t test. * P

    Article Snippet: BT474 human breast cancer cells (HER2-overexpression) were obtained from the American Type Culture Collection (catalog number HTB-20, ATCC) and were cultured in RPMI 1640 supplemented with 10% FBS.

    Techniques: Expressing, Two Tailed Test